Pre-diagnostic circulating resistin concentrations are not associated with colorectal cancer risk in the European Prospective Investigation into Cancer and Nutrition study


  • T.T. Pham
  • K. Nimptsch
  • K. Aleksandrova
  • M. Jenab
  • R. Reichmann
  • K. Wu
  • A. Tjønneland
  • C. Kyrø
  • M.B. Schulze
  • R. Kaaks
  • V. Katzke
  • D. Palli
  • F. Pasanisi
  • F. Ricceri
  • R. Tumino
  • V. Krogh
  • J. Roodhart
  • J. Castilla
  • M.J. Sánchez
  • S.M. Colorado-Yohar
  • J. Harbs
  • M. Rutegård
  • K. Papier
  • E.K. Aglago
  • N. Dimou
  • A.L. Mayen-Chacon
  • E. Weiderpass
  • T. Pischon


  • Cancers


  • Cancers 14 (22): 5499


  • Resistin is a polypeptide implicated in inflammatory processes, and as such could be linked to colorectal carcinogenesis. In case-control studies, higher resistin levels have been found in colorectal cancer (CRC) patients compared to healthy individuals. However, evidence for the association between pre-diagnostic resistin and CRC risk is scarce. We investigated pre-diagnostic resistin concentrations and CRC risk within the European Prospective Investigation into Cancer and Nutrition using a nested case-control study among 1293 incident CRC-diagnosed cases and 1293 incidence density-matched controls. Conditional logistic regression models controlled for matching factors (age, sex, study center, fasting status, and women-related factors in women) and potential confounders (education, dietary and lifestyle factors, body mass index (BMI), BMI-adjusted waist circumference residuals) were used to estimate relative risks (RRs) and 95% confidence intervals (CIs) for CRC. Higher circulating resistin concentrations were not associated with CRC (RR per doubling resistin, 1.11; 95% CI 0.94-1.30; p= 0.22). There were also no associations with CRC subgroups defined by tumor subsite or sex. However, resistin was marginally associated with a higher CRC risk among participants followed-up maximally two years, but not among those followed-up after more than two years. We observed no substantial correlation between baseline circulating resistin concentrations and adiposity measures (BMI, waist circumference), adipokines (adiponectin, leptin), or metabolic and inflammatory biomarkers (C-reactive protein, C-peptide, high-density lipoprotein cholesterol, reactive oxygen metabolites) among controls. In this large-scale prospective cohort, there was little evidence of an association between baseline circulating resistin concentrations and CRC risk in European men and women.